Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02ADM
|
|||
| Drug Name |
Silibinin
|
|||
| Synonyms |
silibinin; Silybin; 22888-70-6; Flavobin; Silymarin I; Silybin A; Silybine; Silibinine; Silliver; Silibinin A; Silibininum; Silibinina; Flavobin Spofa; Silymarine I; Silibinin [INN]; Silymarine; Silibininum [INN-Latin]; Silibinine [INN-French]; Silibinina [INN-Spanish]; 7C3MT; UNII-33X338MNE4; EINECS 245-302-5; NSC 651520; Silimarin; Silibin; CHEBI:9144; 33X338MNE4; Silibinin (INN); NSC651520; C25H22O10; NCGC00091057-01; DSSTox_CID_6018; DSSTox_RID_77985; DSSTox_GSID_26018; (2R,3R)-3,5,7-trihydroxy-2-((2R,3R)-3-(4-hydroxy-
Click to Show/Hide
|
|||
| Indication | Hepatic failure [ICD-11: DB99.7] | Phase 2/3 | [1] | |
| Company |
Meda Pharmaceuticals Somerset, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H22O10
|
|||
| Canonical SMILES |
COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
|
|||
| InChI |
1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
|
|||
| InChIKey |
SEBFKMXJBCUCAI-HKTJVKLFSA-N
|
|||
| CAS Number |
CAS 22888-70-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:9144
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.